RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arix Bioscience Stock

Arix Bioscience EBIT 2024

Arix Bioscience EBIT

-15.14 M GBP

Ticker

ARIX.L

ISIN

GB00BD045071

WKN

A2DL9L

In 2024, Arix Bioscience's EBIT was -15.14 M GBP, a 61.59% increase from the -9.37 M GBP EBIT recorded in the previous year.

The Arix Bioscience EBIT history

YEAREBIT (undefined GBP)
2025e-
2024e-
2023e-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-

Arix Bioscience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arix Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arix Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arix Bioscience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arix Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arix Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arix Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arix Bioscience’s growth potential.

Arix Bioscience Revenue, EBIT and net profit per share

DateArix Bioscience RevenueArix Bioscience EBITArix Bioscience Net Income
2025e0 GBP0 GBP0 GBP
2024e0 GBP-15.14 M GBP0 GBP
2023e0 GBP-9.37 M GBP24.59 B GBP
2022112,000 GBP-5.29 M GBP-27.58 M GBP
2021340,000 GBP-4.73 M GBP-61.08 M GBP
2020480,000 GBP-7.28 M GBP126.3 M GBP
2019510,000 GBP-9.2 M GBP-69.69 M GBP
20181.33 M GBP-10.37 M GBP36.88 M GBP
20171.86 M GBP-9.13 M GBP-7.47 M GBP
2016640,000 GBP-9.66 M GBP-8.84 M GBP
20150 GBP-2.21 M GBP-4.2 M GBP

Arix Bioscience stock margins

The Arix Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arix Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arix Bioscience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arix Bioscience's sales revenue. A higher gross margin percentage indicates that the Arix Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arix Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arix Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arix Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arix Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arix Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arix Bioscience Margin History

Arix Bioscience Gross marginArix Bioscience Profit marginArix Bioscience EBIT marginArix Bioscience Profit margin
2025e-27,375 %0 %0 %
2024e-27,375 %0 %0 %
2023e-27,375 %0 %0 %
2022-27,375 %-4,725.89 %-24,620.54 %
2021-27,375 %-1,391.18 %-17,964.71 %
2020-27,375 %-1,516.67 %26,312.5 %
2019-27,375 %-1,803.92 %-13,664.71 %
2018-27,375 %-779.7 %2,772.93 %
2017-27,375 %-490.86 %-401.61 %
2016-27,375 %-1,509.38 %-1,381.25 %
2015-27,375 %0 %0 %

Arix Bioscience Aktienanalyse

What does Arix Bioscience do?

Arix Bioscience PLC is a leading investment and management provider in the biotech industry. The company is focused on identifying, investing in, and growing emerging companies to develop groundbreaking therapies for patients worldwide. The firm was founded in 2016 in London, United Kingdom, and has since focused on collaborating with emerging biotech companies. Arix is now one of the fastest-growing biotech companies in the region, with locations in London, New York, and Zug, Switzerland. Arix Bioscience's business model is based on investing in young biotechnology companies and supporting their growth. The goal is to develop new drugs and therapies by driving innovation in the biotech industry, ultimately benefiting patients worldwide, including those with rare or incurable diseases. To achieve these goals, Arix Bioscience operates in three divisions: Investment, Management, and Discovery. The Investment division actively invests in young biotech companies that aim to develop and commercialize groundbreaking therapies and new diagnostic methods. The company not only provides financial resources but also has extensive experience in the biotech industry and a variety of contacts to offer advisory support when needed. The Management division focuses on effectively managing investments in young biotech companies to fully unleash their growth potential. Arix Bioscience assists these companies, for example, in finding suitable candidates for leadership positions, planning clinical trials, or exploring new markets. The Discovery division specifically targets the discovery and development of new therapies and medications. The company works directly with biotech startups to create a comprehensive value chain that spans from the discovery and exploration of drug molecules to clinical validation. To achieve these goals, Arix Bioscience collaborates closely with leading biotech startups and research institutions worldwide. The company has extensive relationships and networks in the biotech industry, allowing it to optimize the support it provides to its portfolios. Among the products provided by Arix Bioscience is a portfolio of drugs and therapies developed by the biotech companies in which Arix has invested. These portfolios include successful products such as the CD19 CAR-T therapy developed by Autolus Therapeutics, which is used in cancer treatment. Another example is MiroBio, a company in which Arix Bioscience has invested to develop a new medication for autoimmune diseases. Here too, Arix Bioscience has utilized its investment and management expertise to successfully support the company's growth. Overall, Arix Bioscience is a company with a clear focus on innovation and growth in the biotech industry. The company actively invests in emerging biotech startups and provides targeted management and comprehensive support to lead them to great successes. With its extensive experience, Arix Bioscience has become an important player in the development of new therapies and medications. Arix Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Arix Bioscience's EBIT

Arix Bioscience's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Arix Bioscience's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Arix Bioscience's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Arix Bioscience’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Arix Bioscience stock

How much did Arix Bioscience achieve in EBIT for the current year?

In the current year, Arix Bioscience has achieved an EBIT of -15.14 M GBP.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Arix Bioscience.

How has the EBIT of Arix Bioscience developed in recent years?

The EBIT of Arix Bioscience has increased by 61.591% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Arix Bioscience?

The EBIT of Arix Bioscience is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Arix Bioscience pay?

Over the past 12 months, Arix Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arix Bioscience is expected to pay a dividend of 0 GBP.

What is the dividend yield of Arix Bioscience?

The current dividend yield of Arix Bioscience is .

When does Arix Bioscience pay dividends?

Arix Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arix Bioscience?

Arix Bioscience paid dividends every year for the past 0 years.

What is the dividend of Arix Bioscience?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arix Bioscience located?

Arix Bioscience is assigned to the 'Finance' sector.

Wann musste ich die Aktien von Arix Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arix Bioscience from 9/8/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Arix Bioscience pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Arix Bioscience in the year 2023?

In the year 2023, Arix Bioscience distributed 0 GBP as dividends.

In which currency does Arix Bioscience pay out the dividend?

The dividends of Arix Bioscience are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Arix Bioscience

Our stock analysis for Arix Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arix Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.